Free Biopharma Daily Stock Updates - 09/14/21

$XBI $128.99 -1.59%

---

Covid Updates

$RDHL -32.7% RedHill Biopharma Reports Top-Line Data from Opaganib Phase 2/3 Study in Severe COVID-19 Patients. source

$VALN +3.0% Valneva Completes Recruitment of Elderly Participants in Phase 3 Trial of its Inactivated COVID-19 Vaccine. source

Pipeline Updates

$CALT -13.8% PDUFA goal date extension for Nefecon NDA in the U.S. source

$RNLX -12.5% Mount Sinai Initiates System-wide Scale-Up of Renalytix KidneyIntelX™ Enabled Health Care Model. source

$ANIX -3.6% Anixa Biosciences' Ovarian Cancer CAR-T Therapy to be Discussed at Upcoming Emerging Immunotherapeutics for Ovarian Cancer Symposium. source

$MDNA -1.5% Medicenna Doses First Patient in MDNA11 Phase 1/2 ABILITY Study. source

$RCKT -4.1% Rocket Pharmaceuticals Presents Clinical Data from RP-A501 Trial in Danon Disease at the Heart Failure Society of America (HFSA) Annual Scientific Meeting 2021. source

$AXSM -4.8% Axsome Therapeutics Announces FDA Acceptance of New Drug Application for AXS-07 for the Acute Treatment of Migraine. source

$GRTX -3.4% Galera to Host Virtual Key Opinion Leader Event on Radiotherapy-Induced Severe Oral Mucositis (SOM) in Patients with Head and Neck Cancer. source

$KALV -5.2% KalVista Pharmaceuticals Announces the Lifting of FDA Clinical Hold for Phase 2 Trial of KVD824. source

$ORTX +0.4% Orchard Therapeutics Outlines Differentiated Profile of Its HSC Gene Therapy Approach and Discusses Potential Future Applications at Virtual R&D Investor Event. source

$CHRS -0.6% Positive Interim Results of CHOICE-01 Study Evaluating Coherus' and Junshi Biosciences’ Toripalimab for First Line Treatment of Non-Small Cell Lung Cancer Presented at World Conference on Lung Cancer. source

$KZR +17.4% Presented at H.C. Wainwright Investment Conference on 9/13. source

$BLU +16.5% On 9/13 BELLUS Health Announces Positive Interim Analysis from the Phase 2b SOOTHE Trial of BLU-5937 in Refractory Chronic Cough. source

Finance & Business Updates

$VLON -13.9% Vallon Pharmaceuticals Announces Formation of Scientific Advisory Board. source

$XERS 0% & $SBBP -1.4% XERIS PHARMACEUTICALS STOCKHOLDERS APPROVE ACQUISITION OF STRONGBRIDGE BIOPHARMA. source

$AVTX +1.0% Avalo Therapeutics, Inc. Announces Proposed Public Offering of Common Stock. source

$CMPS -3.5% COMPASS Pathways acquires IP portfolio of novel psychedelic compounds and prodrugs. source

---

Posted by FS